Small cash incentives dramatically improve hepatitis B vaccination rates among injecting drug users

April 9, 2014

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

Researchers in the UK found that people undergoing treatment for who received a maximum total of £30 supermarket vouchers in equal or graduated instalments in return for full compliance with a regimen of three HBV injections were at least 12 times as likely to complete the course within 28 days compared to those not receiving a financial incentive (45% for equal payment instalments and 49% for graduated payment instalments vs 9% for no payment incentive).

The study was led by Professor John Strang from the National Addiction Centre at King's College London, UK, working in close collaboration with senior colleagues at Imperial College London and University College London (UCL), in the UK.

"That monetary incentives increase compliance is unremarkable, but the size of the increase we observed was striking", says Professor Strang. "Injecting users are at high risk of infection and transmission of hepatitis B. This is a potentially life-saving vaccine, and increasing its uptake among this group has important benefits to public health, as well as to the individual."

HBV affects about 22% of injecting drug users in the UK, and much higher proportions in other countries. Medication can slow the spread of HBV, but there is no completely effective cure. It is estimated that 15-25% of people with untreated chronic HBV die of liver disease. A highly effective vaccine exists, but the rate of vaccination uptake is poor. Financial incentive-based public health strategies for treating addiction have gained popularity in the USA in recent years, but such incentive schemes are less common in the UK.

The new study enrolled 210 people receiving opioid substitution therapy from 12 National Health Service drug treatment services across the UK. Services were randomly assigned to different voucher schedules, so that patients received either HBV vaccination without incentive (treatment as usual), fixed value contingency management (£10 voucher at each of three vaccinations), or escalating value contingency management (£5 voucher at first vaccination visit, £10 voucher at second visit, and £15 voucher at third visit).

The researchers compared the effectiveness of these three approaches in achieving completion of vaccination. In the treatment as usual group, only six (9%) of 67 participants completed all scheduled vaccinations, compared with 35 (45%) of 78 participants in the fixed reward group, and 32 (49%) of 65 participants in the escalating reward group.

Additionally, the authors noted that most participants (at least 80%) receiving financial incentives attended appointments on time, ensuring a more efficient use of resources.

According to Professor Strang, "Our research finds that offering financial incentives improves people's completion of HBV vaccination, and can be achieved in routine clinical practice. However, even with these improvements, only about half the participants completed the vaccination schedule in the contingency management groups: more work is needed to refine the reward scheme to increase further the uptake and completion of vaccination."

Writing in a linked Comment, A Thomas McLellan, Director of the Treatment Research Institute in Philadelphia, USA, says, "Health care policy makers might be wise to consider traditional market forces when designing and delivering prevention strategies. The findings from Weaver and colleagues' study suggest that contingent might be as or more important in the disease prevention marketplace as they are in commercial markets."

Explore further: Vaccination campaign doubles HBV mutations

More information: www.thelancet.com/journals/lan … (14)60196-3/abstract

Related Stories

Vaccination campaign doubles HBV mutations

October 7, 2013
A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination ...

Teens susceptible to hepatitis B infection despite vaccination as infants

January 8, 2013
New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue ...

Monitoring inactive hepatitis B patients is cost-effective strategy for Shanghai

January 16, 2014
A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of ...

Financial incentives could help people make healthier life choices

March 12, 2014
(Medical Xpress)—People may be more likely to adopt healthy behaviours if offered small financial incentives, the largest study of its kind has concluded.

Getting personal with hep B vaccines

December 19, 2013
Therapeutic vaccines that boost antiviral immunity provide an attractive alternative to drug therapy for people who are infected with the hepatitis B virus (HBV). Yet, the large amount of genetic diversity found in circulating ...

Half of at-risk flu patients are still not vaccinated

February 3, 2014
(Medical Xpress)—A new study by The University of Nottingham and Boots UK reveals community pharmacy can play an important role in getting more at-risk patients vaccinated against flu, including those with diabetes and ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.